Literature DB >> 3813750

Exercise thallium imaging in patients with diabetes mellitus. Prognostic implications.

J Felsher, M D Meissner, A H Hakki, J Heo, S Kane-Marsch, A S Iskandrian.   

Abstract

We used exercise thallium 201 imaging in 123 patients with diabetes mellitus (77 men and 46 women, aged 56 +/- 8 years), 75% of whom had angina pectoris (typical or atypical). During exercise testing, 18 patients (15%) had angina pectoris, 28 (23%) had ischemic ST changes, and 69 (56%) had abnormal thallium images. During follow-up (up to 36 months), there were 12 cardiac events; four patients died of cardiac causes and eight had nonfatal acute myocardial infarction. Univariate and multivariate survival analysis identified two independent predictors of cardiac events: the event rate was significantly less in patients with normal images and exercise heart rate over 120 beats per minute than in patients with abnormal images and exercise heart rate of 120 beats per minute or less (0% vs 22%). The patients with abnormal images or exercise heart rate of 120 beats per minute or less had an intermediate event rate (11.5%). Furthermore, two of the 54 patients with normal images and ten of 69 patients with abnormal images had subsequent cardiac events. Thus, exercise thallium imaging is useful in risk stratification in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3813750

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  Single-photon emission computed tomography myocardial perfusion imaging in patients with diabetes.

Authors:  Gavin L Noble; Gary V Heller
Journal:  Curr Cardiol Rep       Date:  2005-03       Impact factor: 2.931

2.  Comparison of the treadmill exercise score and single-photon emission computed tomographic thallium imaging in risk assessment.

Authors:  A S Iskandrian; J Johnson; T T Le; V Wasserleben; V Cave; J Heo
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

Review 3.  The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions.

Authors:  J Chris Baldi; Genevieve A Wilson; Luke C Wilson; Gerard T Wilkins; Regis R Lamberts
Journal:  Sports Med       Date:  2016-11       Impact factor: 11.136

4.  Incremental prognostic value of dobutamine-atropine stress 99mTc-tetrofosmin myocardial perfusion imaging for predicting outcome in diabetic patients with limited exercise capacity.

Authors:  Chiara Pedone; Arend F L Schinkel; Abdou Elhendy; Ron T van Domburg; Roelf Valkema; Elena Biagini; Maarten L Simoons; Jeroen J Bax; Don Poldermans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-30       Impact factor: 9.236

5.  Impact on exercise single-photon emission computed tomographic thallium imaging on patient management and outcome.

Authors:  N Nallamothu; S B Pancholy; K R Lee; J Heo; A S Iskandrian
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

6.  Screening of asymptomatic patients with type 2 diabetes mellitus for silent coronary artery disease: combined use of stress myocardial perfusion imaging and coronary calcium scoring.

Authors:  Arthur J H A Scholte; Jeroen J Bax; Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2006 Jan-Feb       Impact factor: 5.952

7.  Detection of coronary artery disease in diabetic patients.

Authors:  C Paillole; J Ruiz; J M Juliard; H Leblanc; R Gourgon; P Passa
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

8.  Cardiac risk assessment in asymptomatic diabetes: combining [corrected] different imaging modalities and surrogate markers?

Authors:  Arthur J H A Scholte
Journal:  J Nucl Cardiol       Date:  2011-05       Impact factor: 5.952

9.  Diagnostic Accuracy of Stress Myocardial Perfusion Imaging in Indian Diabetic Patients: A Single Centre Experience.

Authors:  Deepa Kumar; Ravinder Singh Sethi; Sandeep Bansal; Padma A Namgyal; Aditi Khurana Sehgal; Tajamul Syed Malik
Journal:  Indian J Nucl Med       Date:  2017 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.